Interventional creation of an atrial septal defect and its impact on right ventricular function: An animal study with the pressure-volume conductance system

Background: The aim of our study was to assess the suitability of different interventional techniques to create an atrial septal defect (ASD) and to evaluate the short-term effects of right ventricular (RV) volume overload on RV contractility in the growing swine. Methods: Thirteen ASD and six control animals were studied. An ASD was created by balloon dilatation (BD) of the fossa ovalis (n = 4) or by implantation of a multi-perforated Amplatzer Septal Occluder (n = 4) or a patch-less nitinol device (n = 5). After 4.8 (3.9&#8211;6.0) weeks, the amounts of left-to-right shunting (Qp/Qs) and RV contractility (end systolic elastance &#8212; Ees) were assessed. Results: In the ASD group, a significant left-to-right shunt could be documented (Qp/Qs 1.5 &#177; &#177; 0.4). However, a shunt was absent in the BD subgroup (Qp/Qs 1.1 &#177; 0.1). In animals with devices implanted, a significant relationship between the post-mortem ASD area and Qp/Qs was found (r = 0.68, p < 0.05). Compared to controls, RV contractility was not significantly impaired at rest and during dobutamine in ASD animals (Ees: 0.40 &#177; 0.20 vs 0.54 &#177; 0.12 and 0.75 &#177; 0.29 vs 1.04 &#177; 0.24 mm Hg/mL, p = NS for both). Conclusions: Device implantation is necessary to create a patent ASD resulting in significant left-to-right shunting. In an experimental ASD model, a five week period of chronic RV volume overload does not alter RV contractility significantly. (Cardiol J 2011; 18, 3: 289&#8211;296

Acute and midterm outcomes of the post-approval MELODY Registry: a multicentre registry of transcatheter pulmonary valve implantation

AIMS The post-approval MELODY Registry aimed to obtain multicentre registry data after transcatheter pulmonary valve implantation (TPVI) with the Melody™ valve (Medtronic plc.) in a large-scale cohort of patients with congenital heart disease (CHD). METHODS AND RESULTS Retrospective analysis of multicentre registry data after TPVI with the Melody™ valve. Eight hundred and forty-five patients (mean age: 21.0 ± 11.1 years) underwent TPVI in 42 centres between December 2006 and September 2013 and were followed-up for a median of 5.9 years (range: 0-11.0 years). The composite endpoint of TPVI-related events during follow-up (i.e. death, reoperation, or reintervention >48 h after TPVI) showed an incidence rate of 4.2% per person per year [95% confidence interval (CI) 3.7-4.9]. Transcatheter pulmonary valve implantation infective endocarditis (I.E.) showed an incidence rate of 2.3% per person per year (95% CI 1.9-2.8) and resulted in significant morbidity and in nine deaths. In multivariable Cox proportional hazard models, the invasively measured residual right ventricle (RV)-to-pulmonary artery (PA) pressure gradient (per 5 mmHg) was associated with the risk of the composite endpoint (adjusted hazard ratio: 1.21, 95% CI 1.12-1.30; P 2 improved significantly from 36 [interquartile range (IQR) 24-47] to 12 (IQR 7-17) mmHg and 47 to 1%, respectively (P < 0.001 for each). CONCLUSION The post-approval MELODY Registry confirms the efficacy of TPVI with the Melody™ valve in a large-scale cohort of CHD patients. The residual invasively measured RV-to-PA pressure gradient may serve as a target for further improvement in the composite endpoint and TPVI I.E. However, TPVI I.E. remains a significant concern causing significant morbidity and mortality

Acquired Comorbidities in Adults with Congenital Heart Disease: An Analysis of the German National Register for Congenital Heart Defects

Background: As adults with congenital heart disease (ACHD) are getting older, acquired comorbidities play an important role in morbidity and mortality. Data regarding their prevalence in ACHD that are representative on a population level are not available. Methods: The German National Register for Congenital Heart Defects was screened for ACHD. Underlying congenital heart disease (CHD), patient demographics, previous interventional/surgical interventions, and comorbidities were retrieved. Patients p p < 0.001). On multivariable regression analysis, age and CHD complexity were significantly associated with the presence and number of comorbidities. Conclusions: At least one acquired comorbidity is present in approximately two-thirds of ACHD. Age and complexity of the CHD are significantly associated with the presence of comorbidities. These findings highlight the importance of addressing comorbidities in ACHD care to achieve optimal long-term outcomes

Percutaneous pulmonary polyurethane valved stent implantation

ObjectivesTransfemoral application of pulmonary heart valves has been studied for the past 10 years. Nevertheless, size restriction of percutaneous heart valved stents is still imminent.MethodsIn this study we implanted percutaneously a novel, low-profile polyurethane valved stent. Percutaneous implantation in pulmonary position was evaluated in 7 sheep. The new valved stent fits into a 14F delivery device. The self-expanding nitinol stent was produced by using a dip-coating technique, and a modified commercially available endovascular stent graft system served as a delivery device. The valved stents were deployed directly over the native pulmonary valve under fluoroscopic control. Transthoracic echocardiography was performed after 4 weeks. At the time of explantation, the animals were reanalyzed and killed. Angiography was performed at implantation and at the end of the study. Explanted constructs were analyzed macroscopically and microscopically.ResultsAngiography and echocardiography in all animals demonstrated orthotopic position of the stents at the time of implantation and after 4 weeks. During the deployment procedure, rhythm disturbances occurred in all animals. The peak-to-peak transvalvular gradient was 2.3 ± 1.2 mm Hg initially and 4.1 ± 2.4 mm Hg at follow-up. One-month follow-up confirmed competent neovalves without any paravalvular leakage. Gross morphology demonstrated good opening and closure characteristics. No calcification was seen macroscopically, and surrounding tissue was free of calcification.ConclusionIn the present study we demonstrated successful merging of 2 novel technologies for percutaneous treatment of pulmonary valve diseases using polyurethane stent valve constructs

Acquired Comorbidities in Adults with Congenital Heart Disease: An Analysis of the German National Register for Congenital Heart Defects

Background: As adults with congenital heart disease (ACHD) are getting older, acquired comorbidities play an important role in morbidity and mortality. Data regarding their prevalence in ACHD that are representative on a population level are not available. Methods: The German National Register for Congenital Heart Defects was screened for ACHD. Underlying congenital heart disease (CHD), patient demographics, previous interventional/surgical interventions, and comorbidities were retrieved. Patients &lt;40 years of age were compared to those &ge;40 years. Results: A total of 4673 patients (mean age 33.6 &plusmn; 10.7 years, female 47.7%) was included. At least one comorbidity was present in 2882 patients (61.7%) altogether, and in 56.8% of patients below vs. 77.7% of patients over 40 years of age (p &lt; 0.001). Number of comorbidities was higher in patients &ge;40 years (2.1 &plusmn; 2.1) than in patients &lt;40 years (1.2 &plusmn; 1.5, p &lt; 0.001). On multivariable regression analysis, age and CHD complexity were significantly associated with the presence and number of comorbidities. Conclusions: At least one acquired comorbidity is present in approximately two-thirds of ACHD. Age and complexity of the CHD are significantly associated with the presence of comorbidities. These findings highlight the importance of addressing comorbidities in ACHD care to achieve optimal long-term outcomes